Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | GPR183 | P32249 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.76 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.76 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217648 | 1.00 | CNR1 (1.00) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL3217879 | 1.00 | CNR1 (1.00) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL4459780 | 0.94 | CNR1 (0.88) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL4460020 | 0.90 | CNR1 (0.80) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL4460013 | 0.89 | CNR1 (0.79) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL3224627 | 0.88 | CNR1 (0.92) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL3211855 | 0.88 | CNR1 (0.92) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL3218625 | 0.88 | CNR1 (0.92) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL29618950 | 0.86 | CNR1 (1.00) | CNR1DRD5SLC6A2HTR2AHTR2C | |
| SCHEMBL3215272 | 0.86 | CNR1 (1.00) | CNR1DRD5SLC6A2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896445-B1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| US-20100056513-A1 | STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES | FREI BEAT | 2010-03-04 | — | — | US | claimed |
| EP-1896445-A1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | F. Hoffmann-Roche AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006136502-A1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | claimed |
| US-20060293318-A1 | Stereospecifically substituted benzo[1,3]dioxolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | US | claimed |
| EP-1896445-B1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100056513-A1 | STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES | FREI BEAT | 2010-03-04 | — | — | US | disclosed |
| EP-1896445-A1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | F. Hoffmann-Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136502-A1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293318-A1 | Stereospecifically substituted benzo[1,3]dioxolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293318-A1 | Stereospecifically substituted benzo[1,3]dioxolyl derivatives | CNR1, CNR2, NPY1R | CNR1 1/4885DRD5 263/4885SLC6A2 774/4885 |
| US-20100056513-A1 | STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES | CNR1, CNR2, NPY1R | CNR1 1/4885DRD5 263/4885SLC6A2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.